MBX Biosciences, Inc. announced on January 7, 2025, that its cash, cash equivalents, and marketable securities totaled $262.1 million as of December 31, 2024, figures that are unaudited and preliminary. Additionally, they disclosed positive topline results from their Phase 1 trial for the drug MBX 1416, potentially for the treatment of post-bariatric hypoglycemia. The results suggest MBX 1416 was well-tolerated with a favorable safety profile. The trials support moving into Phase 2 in the second half of 2025. They have also released a press statement on these developments.
*MBX Biosciences, Inc. *Phase 1 Topline Results *MBX 1416 *Post-bariatric Hypoglycemia (PBH) *Phase 2 Trial